Drug Profile
MK 8353
Alternative Names: MK-8353; SCH-900353Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck Sharp & Dohme
- Class Antineoplastics; Dihydropyridines; Indazoles; Pyrrolidines
- Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Solid tumours
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO, Capsule)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO, Capsule)